CA
XBI icon

CSM Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

CSM Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-316,300
Closed -$30M – 137
2024
Q1 		$30M Hold
316,300
– – 1.97% 9
2023
Q4 		$28.2M Buy
+316,300
New +$23.5M 2.03% 9
2023
Q1 		– Sell
-294,100
Closed -$24.4M – 149
2022
Q4 		$24.4M Buy
+294,100
New +$23.8M 2.32% 8

Other funds holding XBI

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

CSM Advisors's XBI Position: Q2 2024 in Review

CSM Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 316,300 shares — an estimated $30M sold.

CSM Advisors first reported a position in XBI in Q4 2022 and held it in 3 quarters. The position peaked at $30M in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

  • CSM Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
  • CSM Advisors sold 316,300 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $30M.
  • CSM Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and held it in 3 quarters.
  • CSM Advisors's State Street SPDR S&P Biotech ETF position peaked at $30M in Q1 2024.
  • 761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on CSM Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.